EULAR 2026 Data: Dapirolizumab, Litifilimab, and CLN-978 Show Promise
Key Questions
What new EULAR 2026 data support dapirolizumab pegol in SLE?
Dapirolizumab pegol (CD40L inhibitor) showed steroid-sparing effects and reduced flares in patients with moderate-to-severe active SLE on standard therapy.
How does litifilimab perform in cutaneous lupus based on recent data?
Litifilimab improved cutaneous lupus activity through 24 weeks with early separation from placebo in clinical measures.
What results were reported for CLN-978 at EULAR 2026?
CLN-978 (CD19xCD3 T cell engager) demonstrated deep B cell depletion, clinical remissions in refractory SLE, and a manageable safety profile with subcutaneous administration.
New data from EULAR 2026: Dapirolizumab pegol (CD40L inhibitor) demonstrates steroid-sparing and flare reduction in SLE. Litifilimab improves cutaneous lupus activity through 24 weeks with early separation. CLN-978 (CD19xCD3 T cell engager) shows deep B cell depletion and clinical remissions in refractory SLE with manageable safety, subcutaneous route. These add to the pipeline of novel targeted therapies for lupus.